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Abstract: Colonization of the gut in early life can be altered through multiple environmental
factors. The present study aimed to investigate the effects of 2’-fucosyllactose (2’-FL), a mixture of
short-chain galactooligosaccharides/long-chain fructooligosaccharides (scGOS/lcFOS) 9:1 and their
combination (scGOS/lcFOS/2’-FL) on dysbiosis induced during rotavirus (RV) diarrhea in neonatal
rats, elucidating crosstalk between bacteria and the immune system. The dietary interventions were
administered daily by oral gavage at days 2–8 of life in neonatal Lewis rats. On day 5, RV SA11
was intragastrically delivered to induce infection and diarrhea assessment, microbiota composition,
and gene expression of Toll-like receptors (TLRs) in the small intestine were studied. All dietary
interventions showed reduction in clinical variables of RV-induced diarrhea. RV infection increased
TLR2 expression, whereas 2’-FL boosted TLR5 and TLR7 expressions and scGOS/lcFOS increased
that of TLR9. RV-infected rats displayed an intestinal dysbiosis that was effectively prevented by
the dietary interventions, and consequently, their microbiota was more similar to microbiota of the
noninfected groups. The preventive effect of 2’-FL, scGOS/lcFOS, and their combination on dysbiosis
associated to RV diarrhea in rats could be due to changes in the crosstalk between gut microbiota and
the innate immune system.
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1. Introduction
Microbial colonization is crucial for early life development of the gut by inducing maturation
of the intestinal epithelium and gut-associated immune system [1]. The composition of commensal
microorganisms, known as microbiota, is subject to dietary and environmental changes, driving
the microbial ecosystem to adapt both qualitatively and quantitatively [2]. In healthy individuals,
there is a balance in the gut microbiota, creating a homeostatic state inside the gastrointestinal
tract which allows for a correctly functioning gut and limits overgrowth of potentially pathogenic
microorganisms. Conversely, the term “dysbiosis” is used to define a state of altered microbiota
composition which comprises structural imbalance as well as changes in the microbial functionality or
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metabolic activities [1]. Intestinal dysbiosis may include overgrowth of potentially harmful commensal
members, reduction or complete loss of normally residing members, and loss of diversity [2,3].
The crosstalk between the immune system and the microbiota has a key role in shaping a healthy
gut environment. The microbial sensing through pattern recognition receptors (PRRs), such as Toll-like
receptors (TLRs) or Nod-like receptors (NLRs) is suggested to influence microbial colonization and
correct immune development [2,4]. Moreover, PRRs play an essential role in the innate immune
system by recognizing microbe-specific and damage-associated molecules, by triggering host defensive
responses, and by providing protection from invading intestinal pathogens. The ligands that activate
PRR signaling pathways are well-known, for example, lipopolysaccharide activates TLR4 and flagellin
activates TLR5 [5]. When this preventive mechanism fails to contain or prevent the infection, pathogens
can trigger excessive inflammation, thereby altering the composition of the microbiota (dysbiosis) and
the barrier function, as seen in animal models [6].
Group A rotaviruses (RVs) are the main cause of dehydrating diarrhea in children under 5 years
of age worldwide, contributing up to 130,000 deaths annually [7]; indeed, almost every child becomes
infected at least once in their first 5 years of life [8]. There is few evidence supporting microbiota
alterations due to RV infection; to date, this link has been suggested at the preclinical level in piglets [9,10]
and in humans [11,12]. Furthermore, the microbiota composition can modulate RV infection and
have an impact in the susceptibility of the disease [13] or in response to RV vaccination [14–17].
Changes in the microbiota, for example, by the use of antibiotics, can also modulate RV infection or
immunization [18,19].
There is increasing interest in the potential of oligosaccharides with prebiotic activity for both
the prevention and treatment of infectious diseases. On the one hand, oligosaccharides exert their
anti-infective activity by stimulating the composition and/or activity of certain commensal bacteria
found in the gut. These changes can induce a broad array of effects, such as an increase of the
production of antimicrobial peptides, the competition for an available ecological niche, or an increase
in short-chain fatty acid (SCFA) production, leading to lower luminal pH and higher mucin production,
thereby contributing to exclude pathogen invasion [20–22]. On the other hand, some oligosaccharides
are considered to have other anti-infective activities independent from those exerted on the commensal
bacteria, such as direct interactions with the immune system, with the intestinal epithelium, or with
the pathogens themselves [23]. Within the complex composition of human milk oligosaccharides
(HMOs), the globally most abundant HMO, 2’-fucosyllactose (2’-FL), has promising effects in vitro
and in vivo by reducing the infectivity or by preventing diarrhea induced by some pathogens,
including RV [10,24–27] as well as improving vaccination responses in vivo [28]. In addition, a mixture
of short-chain galactooligosaccharides (scGOS) and long-chain fructooligosaccharides (lcFOS) at a
proportion of 9:1 has also shown benefits on RV-induced diarrhea in early life [10,27,29,30]. There
are few published studies in regard to the effects of 2’-FL and/or scGOS/lcFOS on human microbiota
composition in healthy conditions [31–33] and even less in the context of RV infection; only preclinical
data is available in a piglet model [10]. On the other hand, it has been recently described the importance
of the interaction between HMOs and microbiome of milk, as well as neonatal microbiome on rotavirus
infection [34].
Therefore, we aimed to investigate the effects of 2’-FL, scGOS/lcFOS, and their combination on the
dysbiosis caused by RV diarrhea in neonatal rats. Moreover, changes in the bacteria–host crosstalk that
could be linked to microbiota composition and oligosaccharides anti-infective effects were studied.
2. Materials and Methods
2.1. Animals
Fifteen G15 pregnant Lewis rats (LEW/OrlRj) were provided by Janvier Labs (Le Genest Saint Isle,
France), individually housed in cages (2184L Eurostandard Type II L, Tecniplast, West Chester, PA,
USA) with large fibrous particles bedding (Souralit 1035, Bobadeb S.L., Santo Domingo de la Calzada,
Cells 2019, 8, 876 3 of 19
Spain) and tissue papers (Gomà-Camps S.A.U., La Riba, Spain), and monitored daily. After natural
delivery, litters were randomly assigned to the experimental groups and culled to 8 pups per lactating
dam, with a similar number of females and males in each litter. Dams received a commercial diet
(Teklad Global Diet 2014, Envigo, Indianapolis, IN, USA) and water ad libitum. Animal handling
was performed during the first hours of the light phase on a scheduled basis to limit the disturbance
and influence of biological rhythms. After separating all the mothers and keeping the pups in the
home-cage, handling and oral administration was performed. Afterwards, the dam was reunited with
the whole litter. They were housed under controlled conditions of light (12 h light–12 h dark cycle),
temperature, and humidity in a biosecurity level 2 isolated room in the Faculty of Pharmacy and Food
Science animal facility (University of Barcelona, Spain). All experimental procedures were approved
by the Ethical Committee for Animal Experimentation of the University of Barcelona and the Catalonia
Government (CEEA-UB Ref.74/05, DAAM: 3046).
In regard to sample size estimation, three litters were required for each group as previous studies
have demonstrated a remarkable variability among litters [30]. The Appraising Project Office’s program
from the Universidad Miguel Hernández de Elche (Alicante) was used to calculate the minimal sample
size to provide statistically significant differences among groups. The final number of animals was not
affected by the dropouts or outliers, which did not occur in the present study.
2.2. Experimental Design
The present study is part of a larger project (“Preventive antidiarrhoeic effect of scGOS/lcFOS and
2-FL on a rat neonatal RV infection model”) in which neonatal rats were given the same oligosaccharides
from the second to the sixteenth day of life, aiming to evaluate global clinical outcomes and modulation
of the immune response throughout and at the end of the diarrheic period [27]. Herein, the study
focuses on the effect of the oligosaccharides on the fecal microbiota composition at the peak of the
diarrhea induced by RV, corresponding to day 8 of life.
scGOS/lcFOS and 2-FL were selected for the study because they are oligosaccharides already
added to infant formula with anti-infective and immunomodulatory effects both at the preclinical and
human levels [24–30].
Upon natural delivery, newborn rats were randomly distributed into five groups depending on
the supplementations given (provided by Danone Nutricia Research, Utrecht, The Netherlands)—the
reference (REF), rotavirus-infected (RV), and rotavirus-infected—and that received: a) a mixture of
scGOS and lcFOS in a 9:1 ratio (RV+scGOS/lcFOS); b) 2’-FL (RV+2’-FL); and c) both scGOS/lcFOS and
2’-FL (RV+scGOS/lcFOS/2’-FL). The analyses of the oligosaccharides were performed by either high
performance anion exchange chromatography (HPAEC) or liquid chromatography-mass spectrometry
(LC-MS) as previously described [35,36].
Neonatal rats were orally administered from the second to the eighth day of life, when the diarrhea
reaches its maximum score, as previously described [29]. The RV+scGOS/lcFOS group was given
0.8 g of scGOS/lcFOS per 100 g of body weight (4.5 µL/g/day), the RV+2’-FL group was given 0.2 g
of 2’-FL/100 g of body weight (4.5 µL/g/day), and the RV+scGOS/lcFOS/2’-FL group received both
products at the same doses as when administered separately (4.5 µL/g/day). A matched volume of
water was administered to the animals from the REF and RV groups. 2’-FL was produced by microbial
fermentation, with >90% purity. The selected dose of GOS/FOS was based on previous studies in
similar approaches [29] and that of 2-FL was based on the daily consumption of an infant of this
particular HMO per body weight [37,38] and on previous studies [27,39]. In addition, it has been
demonstrated to be a safe dose in rats [40].
The RV (simian SA-11) was obtained as previously described [41] and inoculated at day 5 of
life (4 × 108 Tissue Culture Infectious Dose 50 [TCID50]/rat) in all the experimental groups with the
exception of the REF group, which received the same volume of PBS under the same conditions. At day
8 of life, 3 days after RV inoculation, half of each litter (4 random pups, 3 litters/group, n = 12) were
euthanized to obtain tissue samples for the current study.
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2.3. Clinical Evaluation and Sample Collection
Fecal sampling was performed once daily throughout the study (from day 4 to day 8 of life) by
gently pressing and massaging the abdomen. Severity of diarrhea was expressed by fecal weight and
by scoring fecal samples from 1 to 4 (diarrhea index, DI) based on color, texture, and amount as follows:
normal feces (1); soft yellow-green feces (2); totally loose yellow-green feces (3); and high amount
of watery feces (4). Sample scoring was performed by two senior investigators in a blinded manner.
Scores ≥ 2 indicate diarrheic feces, whereas scores < 2 indicate absence of diarrhea [41]. Fecal samples
were weighed and stored at −80 ◦C until the analysis of the microbiota composition.
Incidence of diarrhea was expressed by the percentage of diarrheic animals (%DA), which is
based on the percentage of animals displaying scores of DI ≥ 2 in each group. The DI and %DA were
normalized in the groups receiving scGOS/lcFOS and scGOS/lcFOS/2’-FL because of intrinsic effects on
the fecal consistency of each supplementation. For the normalization, the mean DI was calculated for
the timepoints when there was no active diarrhea in the RV group (before the infection on days 4–5
and after the diarrhea was resolved on days 12–16). The difference between this mean and the baseline
score of DI = 1 was subtracted to all values of DI for RV+GOS/FOS and RV+GOS/FOS+2’-FL groups.
At day 8 of life, neonatal rats were intramuscularly anesthetized with ketamine (90 mg/kg) (Merial
Laboratories S.A., Barcelona, Spain) and xylazine (10 mg/kg) (Bayer A.G., Leverkusen, Germany) and
exsanguinated. A section of 1 cm of the central part of the small intestine was collected in RNA later
for the gene expression analysis.
2.4. Quantification of Gene Expression by Real-Time PCR
As previously described [42], the small intestine, including duodenum, jejunum, and ileum,
was obtained and 1 cm portion of the central section of the whole intestine was sectioned. It was
homogenized during 30 s in lysing matrix tubes (MP Biomedicals, Illkirch, France) using a FastPrep-24
instrument (MP Biomedicals). RNA was isolated with the RNeasy®Mini Kit (Qiagen, Madrid, Spain)
following the manufacturer’s instructions. RNA purity and concentration were determined with a
NanoPhotometer (BioNova Scientific S.L., Fremont, CA, USA). Later, cDNA was obtained in a thermal
cycler PTC-100 Programmable Thermal Controller using TaqMan®Reverse Transcription Reagents
(Applied Biosystems, AB, Weiterstadt, Germany).
The specific PCR TaqMan®primers (AB) used to assess gene expression with real-time PCR
(ABI Prism 7900 HT, AB) were Tlr2 (Rn02133647_s1, inventoried, I), Tlr3 (Rn01488472_g1, I), Tlr4
(Rn00569848_m1, I), Tlr5 (Rn04219239_s1, I), Tlr7 (Rn01771083_s1, I), and Tlr9 (Rn01640054_m1, I).
The relative gene expression was normalized with the housekeeping gene Gusb (Rn00566655_m1,
I) using the 2-∆∆Ct method [43]. The results are expressed as the percentage of expression in each
experimental group normalized to the mean value obtained for the REF group, which was set at 100%.
2.5. Analysis of Fecal Microbiota Composition by 16S rRNA Sequencing
A representative animal from each litter was included in the microbiota composition analysis
(3 litters/group, n = 3). For that, the selected animal in each litter met the following criteria: being
an animal with a fecal sample collected on day 8 and not being one of the animals with the highest
or the lowest DI scores. Genomic DNA was extracted from the fecal samples ranging 5–20 mg
collected on day 8, using the Qiamp DNA Stool Mini kit (Qiagen) with some previous modification,
enzymatic lysis, and mechanic disruption [44]. Extra purification and concentration were performed
following the cleaning protocol from the Qiamp Micro kit (Qiagen). DNA concentrations obtained
were 6.6 ng/µL (from 1.3 to 22.3 ng/µL) with purities of 1.89 for A260/280 and 0.36 for A260/230. In all
cases, enough DNA was obtained and 50 ng of DNA were amplified following the 16S Metagenomic
Sequencing Library Illumina 15044223 B protocol (Illumina Inc, San Diego, CA, USA) in collaboration
with Lifesequencing S.L (Valencia, Spain). In brief, in the first amplification step, primers were designed
containing a universal linker sequence allowing amplicons for incorporation indexes, sequencing
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primers by Nextera XT Index kit (Illumina Inc.), and 16S rRNA gene universal primers for the V3–V4
regions [45]. In the second and last amplifications, indexes were included. Libraries were quantified by
fluorimetry using the Quant-iT™ PicoGreen™ dsDNA Assay Kit (Thermo Fisher Scientific) and pooled
prior to sequencing on the MiSeq platform (Illumina Inc.), with a configuration of 300 cycle paired
reads. The size and quantity of the pool were assessed in the Bioanalyzer 2100 (Agilent) and with the
Library Quantification Kit for Illumina (Kapa Biosystems Inc., Wilmington, MA, USA), respectively.
PhiX Control library v3 (Illumina Inc.) was combined with the amplicon library (expected at 20%).
Sequenced data were available within approximately 56 h. Image analysis, base calling, and data
quality assessment were performed in the MiSeq instrument.
The software Paired-End read merger (PEAR v 0.9.6, Exelixis Lab, Heidelberg, Germany) was
used to merge raw sequences forward and reverse in order to obtain the complete sequence. Using this
approach, the ends of the obtained sequences were overlapped in order to get complete sequences.
The amplification primers from the sequences obtained in the sequencing step were trimmed with
Cutadapt v1.8.1 [46], using parameters by default, in order to reduce the bias in the annotation
step. Once the primers had been removed, sequences lower than 200 nucleotides were excluded
from the analysis because short sequences have a higher chance to generate wrong taxonomical
group associations.
After obtaining the clean complete sequences, a quality filter was applied in order to delete
sequences with poor quality. Those bases in extreme positions that did not have Q20 (99%) of
well-incorporated bases in the sequencing step or more Phred quality score were removed, and later,
sequences of which quality means did not surpass the Q20 threshold, as a mean quality of the whole
sequence, were also deleted. The resulting sequences were inspected for PCR chimera constructs
that may occur during the different experimental process, which were removed from further analysis.
Each group of sequences was compared to a database of rRNA using an alignment BLAST strategy
to associate taxonomic groups. The relative proportions of phyla, families, genus, and species were
calculated. Moreover, to estimate the specific biodiversity, the Shannon Index and CHAO1 indexes
were calculated.
To visualize the presence or absence of certain bacterial genera and species in the experimental
groups, the criteria used were all bacterial groups detected in 2 or 3 animals with proportions higher
than 0.001% were regarded as present, while the bacterial groups detected in just 1 animal or none were
regarded as absent. On that basis, the Venn diagrams were constructed to visualize numerically how
the genera and species were distributed among the groups in order to compare their coincidences and
differences. Furthermore, the log2 fold change of all genera and species was calculated with respect to
the RV group and were represented in heat maps. Finally, sequences that closely resemble bacterial
strains with accepted probiotic activity [47] were selected and represented in a heat map by calculating
their relative percentage in each group, where the group with the highest bacterial count was set at
100% and the group with the lowest bacterial count at 0%.
2.6. Principal Components Analysis
Principal Components Analysis (PCA) was conducted to evaluate the dimensionality of microbiota
profile with regard to the infection and oligosaccharide supplementations. To develop the model,
Simca v14.1 was used (Umetrics, Umeå, Sweden). Two data matrices were constructed consisting of
15 rows (15 samples/group) and 100 variables corresponding to the taxonomic analysis of genera or
189 variables corresponding to the taxonomic analysis of species. PCA was conducted on both data
matrices in order to explore the presence of any natural clustering in the data. In the preprocessing of
the PCAs, the mean-centering and unit variance scaling were applied.
2.7. Statistical Analysis
The Statistical Package for the Social Sciences (SPSS v22.0) (IBM, Chicago, IL, USA) was used
for statistical analysis. Data was tested for homogeneity of variance and normality distribution by
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the Levene’s and Shapiro–Wilk tests, respectively. When data was homogeneous and had a normal
distribution, conventional one-way ANOVA test followed by the post-hoc Bonferroni was performed.
Otherwise, the nonparametric Kruskal–Wallis test followed by the post-hoc Mann–Whitney U test were
performed. Due to the limited sample size, the distribution of the resulting p-values was such that it
did not allow proper multiple testing correction. The Chi-square test was used to compare frequencies
of diarrhea incidence (%DA). Finally, correlations of clinical data with TLRs gene expression and
microbiota levels were performed by calculation of the Pearson’s correlation coefficient. Differences
were considered significant when p < 0.05.
3. Results
3.1. Clinical Assessment
RV inoculation in rats induced a moderate acute diarrhea, displaying the highest affectation at
day 8 of life (3 days after RV inoculation). The severity of diarrhea, calculated as the DI (Figure 1a),
was significantly reduced for both RV+scGOS/lcFOS and RV+scGOS/lcFOS/2’-FL (p < 0.05 vs. RV),
whereas although the 2’-FL group displayed a lower severity, no statistical differences were seen as
compared to the control RV infection. Moreover, when calculating the percentage of diarrheic animals
(%DA) as an indicator of incidence (Figure 1b), all three supplementations were able to profoundly
reduce the proportion of animals displaying diarrhea (DI ≥ 2); indeed, none of the animals in the
RV+scGOS/lcFOS and RV+scGOS/lcFOS/2’-FL groups displayed diarrhea and only 10% in RV+2’-FL
group did. Although on day 8 only 50 % of the animals displayed diarrhea in the RV group, almost all
animals (21/24, 87.5%) displayed DI ≥ 2 at some timepoint of the diarrhea process because some of
them reached the peak of the disease on days 6 or 7. In fact, the day in which the maximum score was
obtained was 7.54 ± 0.20 for the RV group, 7.40 ± 0.87 for the GOS/FOS group, 6.83 ± 0.32 for the 2-FL
group, and 6.25 ± 0.25 for the group receiving the combination of both products. The fecal weight,
as an objective indicator of the disease, increased due to RV diarrhea. However, such increase was
prevented by supplementation with all the oligosaccharides (Figure 1c), being statistically different for
the RV+2’-FL and RV+scGOS/lcFOS/2’-FL groups (p < 0.05 vs. RV group).
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Figure 1. Clinical variables of severity and incidence of diarrhea on day 8: (a) The Diarrhea Index (DI)
is based on scoring fecal samples from 1 to 4 depending on the color, texture, and abundance. Scores of
DI ≥ 2 indicate the presence of diarrhea, whereas scores < 2 indicate the absence of diarrhea. (b) The
percentage of diarrheic animals (%DA) is based on the percentage of animals displaying DI scores ≥ 2 in
each group. (c) The mean fecal weight was calculated in each group as an objective indicator of diarrhea
severity. The results are expressed as mean ± S.E.M. (n = 8–12/group, depending on the number of
fecal samples obtained) * p < 0.05 compared to the reference (REF) group; # p < 0.05 compared to the
RV group ((a) by ANOVA; (b) by the Chi Squared test; and (c) by the Mann–Whitney U test).
3.2. Intestinal Toll-Like Receptors Expression
In order to better understand the role of oligosaccharide supplementation in the immune response
and its crosstalk with the microbiota in the context of RV infection, the gene expression of Toll-like
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receptors (TLRs) was assessed by real-time PCR (Figure 2). The highest expression in REF rats was
found in TLR3, TLR4, and TLR9 (Figure 2a). RV infection did not alter considerably the gene expression
of the TLRs studied, with exception of TLR2, which was increased in the RV group (p < 0.05, Figure 2b).
Similarly, the dietary supplementations with 2’-FL and its combination with scGOS/lcFOS increased
other TLRs gene expression compared to the REF and RV groups, such as TLR5 and TLR7 (p < 0.05).
In addition, rats receiving scGOS/lcFOS also increased significantly the expression of TLR9 (p < 0.05 vs.
the RV and REF groups). The expressions of TLR3 and TLR4 were not modified either by the infection
or the supplementations. Despite that, TLR4 gene expression positively correlated with the DI when
clustering all RV-infected animals together (r = 0.422, p < 0.05).
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Figure 2. Small intestine gene expression of Toll-like receptors (TLRs) at the peak of diarrhea (day 8):
The transcription of TLR2, 4, 5, 7, and 9 were quantified by real-time PCR. (a) The ∆Ct of TLR expression
compared to Gusb was calculated in REF animals. (b) The relative gene expression in the experimental
groups was calculated with respect to REF, which corresponded to 100% of transcription. Results are
expressed as mean ± S.E.M. (n = 8/group). * p < 0.05 compared to the REF group; # p < 0.05 compared
to RV group (by the Mann–Whitney U test).
3.3. Fecal Microbiota Composition
3.3.1. Overall Diversity
The fecal microbiota composition was assessed during the peak of diarrhea in order to ascertain
whether the RV infection or the supplementation with oligosaccharides in the presence of RV were
able to alter the microbial populations. No differences were observed in the number of sequences
and Operational Taxonomic Units (OTUs, Table 1). Moreover, the Shannon Index and the CHAO1,
indicating diversity and richness of the microbial community, respectively, were similar among groups
(Table 1).
Table 1. Overall diversity of fecal microbiota at the peak of diarrhea (day 8).
REF RV RV+scGOS/lcFOS RV+2’-FL RV+scGOS/lcFOS/2’-FL
Number of sequences 39248 ± 2944 38902 ± 982 41732 ± 1528 31028 ± 3510 36070 ± 1703
Number of OTUs 103 ± 9 113 ± 12 124 ± 9 143 ± 39 104 ± 22
Shannon Index 1.68 ± 0.08 1.61 ± 0.07 1.74 ± 0.05 1.92 ± 0.17 1.61 ± 0.04
CHAO1 Richness 259.7 50.2 285.0 ± 60.4 251.7 7.9 263.0 ± 46.0 187.0 ± 46.5
16S rRNA gene v3–v4 was sequenced by the Metagenomic Sequencing Library Illumina 15044223 B protocol.
The Shanno Index and CHAO1 estimator were calculated according to the Operational Taxonomic Units (OTU)
numbers of each group. Results are expressed as mean ± S.E.M. (n = 3/group). No statistical differences were found
(by the Mann-Whitney U test).
3.3.2. Taxonomic Analysis
The taxonomic analysis of the microbial populations showed that Firmicutes and Proteobacteria
were the most abundant phyla in the neonatal rat fecal microbiota (Figure 3a). RV infection did not
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change the proportion of the different phyla, although a tendency to reduce microorganisms from the
Actinobacteria phylum was detected in all RV-infected groups compared to REF. The supplementations
with oligosaccharides did not show relevant differences either, with the exception of increasing the
Proteobacteria proportion in the scGOS/lcFOS group (p < 0.05 vs. REF).
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Figure 3. Main taxonomic ranks showing the proportion of bacterial populations in the fecal content
at the peak of diarrhea (day 8): The sequencing of the amplicon targeting the V3–V4 region of the
16S rRNA was performed following the 16S Metagenomic Seque cing Library Illumina 15044223 B
prot c l. The relative proportion of t t i s calculated in each taxonomic rank: (a) phylum,
(b) family, (c) genus, and (d) species. The res sed as ean (n = 3/group). Significant
differ nces are shown only in the text (by the test).
In contrast, the fa ily abund nce of the neonatal rat fecal m crobiota as notably changed by
both the RV infection and the oligosaccharides supplementations (Figure 3b). The RV grou decreased
the proportion of Streptococcaceae with respect to REF (p < 0.05), which was prevented by he three
supplementations. Indee , the supplementation with scGOS/lcFOS and scGOS/lcFOS/2’-FL had a
higher proportion of this family than the RV group (p < 0.05). On the other hand, the RV group showed
a trend to reduce the members of the Staphylococcaceae family compared to the REF group, whereas the
administration of scGOS/lcFOS and 2’-FL increased their proportion in comparison with the RV group
(p < 0.05).
The analysis of microbiota at the genus level (Figure 3c) did not show notable changes in
Lactobacillus or Escherichia, which totaled more than 60% of the neonatal fecal population. Nevertheless,
the RV+2’-FL and RV+scGOS/lcFOS/2’-FL displayed a reduction in the proportion of the Rothia genus
(the third most abundant) compared to the REF group (p < 0.05).
Interestingly, the lower proportion of Streptococcaceae by RV infection caused a decrease in
Streptococcus which was prevented by scGOS/lcFOS and scGOS/lcFOS/2’-FL supplementations
(p < 0.05). Similarly, the decrease in Staphylococcaceae was due to the reduction in the proportion of
Staphylococcus in the RV group which was counteracted by the supplementation with scGOS/lcFOS
and 2’-FL administration.
The supplementations also induced changes in minor populations compared to both the RV and
REF groups (Figure 3c, included in the section termed “others”). All oligosaccharides showed an
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increase in genera belonging to the Firmicutes and Actinobacteria phyla. For example, scGOS/lcFOS and
its combination with 2’-FL increased Turicibacter compared to the REF and RV groups (0.077± 0.032% and
0.039 ± 0.023% vs. 0.005 ± 0.001% and 0.002 ± 0.001%, respectively; p < 0.05). Moreover, scGOS/lcFOS
had a tendency to increase Bifidobacterium compared to the REF and RV groups (0.194 ± 0.194% vs.
0.014 ± 0.011% and 0.006 ± 0.003%, respectively). This trend towards an increase in Bifidobacterium was
even higher in the animals receiving 2’-FL (up to 0.555 ± 0.283%).
More than 90% of the microbiota composition comprised 7 species (Figure 3d). All RV-infected
groups tended to increase the levels of Enterococcus faecalis, which only attained statistical significances
in the RV+scGOS/lcFOS group (p < 0.05 vs. REF). Moreover, all RV-infected groups reduced the levels
of Streptococcus sanguinis compared to the REF group (p < 0.05). The supplementations induced other
specific changes, such as a decrease in the proportion of Lactobacillus animalis in the RV+scGOS/lcFOS and
RV+scGOS/lcFOS/2’-FL groups compared to both the REF and RV groups (p < 0.05). Moreover, animals
administered only with scGOS/lcFOS showed an increase in the proportion of Lactobacillus reuteri
(p < 0.05 vs. REF).
In order to better visualize and combine both the qualitative and quantitative proportions of the
genera and species present in feces, two heat maps were created (Figure 4 and Figure S1). Hence,
it was found that RV infection promoted the colonization of genera from the Proteobacteria phylum
(e.g., Hyphomicrobium, Klebsiella, or Rhodobacter), which were not detected in the REF group. Moreover,
most of these genera were not found either in the groups administered with scGOS/lcFOS, 2’-FL or the
combination of both. In addition, concerning Firmicutes phylum, Clostridium was not detected in the
RV group but it was detected in all the other groups.
Correlation analysis between microbiota, clinical outcomes, and TLRs was also performed. The
DI positively correlated with 8 genera (p < 0.05, Chelativorans (r = 0.958), Hyphomicrobium (r = 0.903),
Klebsiella (r = 0.958), Methylotenera (r = 0.968), Pediococcus (r = 0.813), Rhodobacter (r = 0.834), Sinibacillus
(r = 0.958), and Thauera (r = 0.958)), which were exclusively found in the RV group with the
exception of Pediococcus, which was also present in the groups administered with scGOS/lcFOS and
scGOS/lcFOS/2’-FL. However, it should be taken into account that these genera were not abundant
because their proportions in the samples were lower than 0.005%. Moreover, the correlations between
microbiota and TLRs were also analyzed gathering all the infected groups. Although 30 genera
correlated with the expression of some TLRs, 28 of them were with genera poorly represented in
the samples (<0.01%). From the remaining genera, negative correlations between the proportion of
Lactobacillus and TLR5 (r = −0.755, p < 0.05) and of Rothia and TLR9 (r = −0.921, p < 0.05) were found.
3.3.3. Venn Diagrams and Principal Components Analysis: Genera and Species
The impact of RV infection and oligosaccharides supplementation on fecal microbiota genera and
species was further assessed by an analysis of Venn diagrams and PCAs (Figure 5). Venn diagrams
allowed the observation of these differences numerically (Figure 5a). This approach could possibly
reduce the background variability represented by transient or subject-specific microbes, allowing the
better characterization of those changes due to RV infection and oligosaccharides supplementation.
There was a core of 19–21 bacterial genera, which persisted in all three groups and accounted for
more than 95% of the microbiota. Comparing the microbiota of the REF and RV groups at the genus
level, a remarkable qualitative alteration of the fecal microbiota due to the infection can be observed.
The RV caused a dysbiosis observed by the colonization of 20 new genera (e.g., Klebsiella, Pediococcus,
and Rhizobium) while 4 of the genera present in the REF group were not detected (Burkholderia,
Clostridium, Melissococcus, and Rudaea).
In regard to the supplementations, several of those genera that appeared due to the infection
(13–16 out of the 20 in the RV group) were not detected after the oligosaccharide interventions. Instead,
14–18 new genera, which were absent in either the RV or the REF groups, colonized the intestine
(e.g., Pasteurella, Roseburia, and Ruminococcus).
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Figure 4. Summary of genera variation in fecal microbiota at the peak of diarrhea (day 8): A heat map
of the mean relative abundances of the prominent OTUs assigned to the genus level is represented.
The rows represent the genera and the columns the experimental groups. The log2 of the fold change
with respect to the RV group was calculated and assigned a color following the legend. Genera which
were present in a group but not in the RV group were assigned the maximum variation (>3.5, marked
with a “+”), whereas the genera which were presented in the RV group and not in the other groups were
assigned the minimum variation (<−3.5, marked with a “-“). The results are derived from n = 3/group.
VM: Verrucomicrobia.
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The analysis of species with the Venn diagram approach showed similar results, maintaining a
core of 35–42 species in all groups as the main bacterial populations independently of the infection and
supplementations. In addition, several RV- and supplementation-specific species that colonized the
intestine were modified (Figure 5a).
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Analysis of the fecal microbiota diversity in genera and species at the peak of diarrhea
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genera and species. To estimate the presence or the absence of these taxa in the experimental groups,
it was agreed that all groups displaying 2 or 3 animals (out of the 3 analyzed in each group) with a
bacterial proportion were computed as present, while the groups displaying 1 animal or none were
computed as absent. The results are derived from n = 3/group.
PCAs were plotted (Figure 5b) in order to reduce the dimension of these taxonomic data while
retaining the maximum variation (a cumulative 56.3% and 51.4% on PC1 until PC3 for genera and
species, respectively). The microbiota of the RV group clearly clustered apart from those of the REF
group and the oligosaccharide-receiving groups infected with RV in both the analysis of genera and
species. In contrast, the REF animals and those receiving oligosaccharides clustered together in the
case of species but not so clearly in the case of genera because the supplementations seemed to induce
some changes that clustered them apart from 2 individuals of the REF group.
3.3.4. Assessment of Prebiotic Potential of Oligosaccharides
The prebiotic activity of the oligosaccharides was also assessed by observing the relative
abundance in selected bacterial species that have been attributed probiotic properties (Figure 6).
All supplementations induced a clear prebiotic effect, as seen by higher relative counts of these
beneficial microorganisms. In particular, scGOS/lcFOS supplementation induced the highest prebiotic
effect promoting the growth of Lactobacillus gasseri, Lactobacillus reuteri, Lactobacillus rhamnosus, and
Bifidobacterium animalis, whereas 2’-FL induced an increase in Lactobacillus crispatus, Lactobacillus
johnsonii, Lactobacillus reuteri, and Bifidobacterium animalis populations. No correlations between the
proportion of these species, and the DI were observed.
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Figure 6. Analysis of the main bacterial species with probiotic activity found in the fecal microbiota at
the peak of diarrhea (day 8): The heat map displays the relative abundance of bacteria with probiotic
activity, where the group with the highest abundance was set at 100% and the group with the lowest
abundance was set at 0%. The results were derived from n = 3/group.
4. Discussion
Throughout early life, virtually all infants are exposed to RV infection, leading to vomiting,
fever, and diarrhea. In this study, oligosaccharide supplementations have shown beneficial
immunomodulatory effects, such as the increase in TLR expression, which we hypothesize could
indicate a better sensing and clearance of the RV. In addition, we have shown for the first time that the
challenge with RV SA11 in suckling rats induces intestinal dysbiosis and that this disturbed microbiota
can be prevented by the administration of certain oligosaccharides (Figure 7).
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and crosstalk: (a) Microbial imbalance produced by the RV infection in the neonatal rat model in terms
of crosstalk alterations and microbiota composition with respect to a noninfected group (REF) and
(b) Preventive effects of scGOS/lcFOS and 2’-FL on the dysbiosis caused by the RV.
The challenge with RV in 5-day suckling rats induced moderate diarrhea, which displayed the
highest clinical symptoms at 3 days postinoculation (day 8), when the incidence was 50% in the RV group.
The present results demonstrate that both 2’-FL and GOS/FOS, as well as their combination,
displayed amelioration in terms of the severity and incidence of RV infection. These results agree with
previous studies in our group [27,29,30,48]. In regard to the mechanisms by which oligosaccharides
can prevent infections, they might involve both microbiota-independent and microbiota-dependent
actions [49]. Our previous studies were focused on microbiota-independent mechanisms, the direct
effect on the virus, and the gut epithelial and immune cells, evidencing that the mechanisms involved
were different between both oligosaccharides. 2’-FL displayed a higher direct ability to promote
intestinal maturation and to enhance neonatal immune responses, whereas GOS/FOS induced an
intestinal trophic effect and a higher RV-blocking action, and their combination showed additive
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effects in some variables [27]. These effects are in line with the prevention of pathogen binding
and the modulation of intestinal epithelial and immune cell response effects ascribed to certain
HMOs [37]. Besides this, the present study has focused on the microbiota-dependent mechanisms
of these oligosaccharides by means of the study of the TLR gene expression as a first approach to
evaluate bacteria-host interaction and the study of their ability to modulate gut microbiota composition.
Some oligosaccharides have been attributed immunomodulatory activities regarding TLR functionality,
as they may act directly as TLR ligands or indirectly, for example, by changing the microbiota and
thus the immunoreactive profile [4,50–53]. The gene expression of several intestinal TLRs was boosted
by the RV infection and the supplementations. On the one hand, the challenge with RV induced a
higher expression of TLR2 in all groups (with exception of the RV+scGOS/lcFOS group, which only
displayed a trend to increase). This fact could be explained by considering the ability of TLR2 to
recognize RV Non-Structural Protein 4 (NSP4), which is a glycoprotein playing an essential role in
the RV assembly and acting as an enterotoxin capable of inducing diarrhea [54,55]. On the other
hand, the supplementation with 2’-FL and scGOS/lcFOS/2’-FL increased the levels of TLR5 and TLR7
compared to both the RV and REF groups. These innate receptors are involved in the sensing of
bacterial flagellin and ssRNA, respectively. TLR5 is crucial in the sensing of commensal bacteria, and its
loss has shown to alter the normal gut microbiome leading to a dysbiosis characterized by chronic
intestinal inflammation and outgrowth of Proteobacteria, far more motile than normal and with a high
source of pro-inflammatory flagellin in the gut [56]. In this context, the increase of TLR5 displayed by
2’-FL and scGOS/lcFOS/2’-FL supplementations at the peak of RV infection would suggest a higher
resistance to dysbiosis, a fact which was also supported by the preventive ability in the colonization of
many genera of the Proteobacteria phylum that appeared in the RV group. Moreover, it is suggested
that the activation of TLR5/NLRC4 is involved in the cure and prevention of RV infection [57] and that
mRNA levels of TLR5 do not seem to be changed by the absence or presence of gut microbiota [58].
The rise in TLR7 expression would also mean a higher antiviral state, as TLR7 has been shown to
trigger interferon (IFN)α/β expression [59]. Indeed, such increase could indicate a better sensing and
response against RV, which although it is a dsRNA virus, some studies suggest that its genetic material
can be degraded towards ssRNA in the endosomal compartment and, therefore, can be recognized by
TLR7 [59–61] (Figure 7).
It would be interesting to know whether, besides these changes in TLR gene expression, a
direct interaction of the tested oligosaccharides with the TLR or even with host lectins is produced.
The microbiota composition in the human neonatal gut is mainly driven by the host environment,
delivery mode (vaginal/caesarian), and type of feeding (breast/formula) [62]. This microbial population
changes rapidly over time until 2 to 3 years of age, when it stabilizes towards an adult-like
configuration [63]. In the first week of life, microbiota is frequently dominated by facultative
anaerobes, which consume oxygen, and thus afterwards, they make the habitat suitable for the
colonization by strict anaerobes [64]. This principle of succession in rodents resembles that in humans,
although it shows a differential pattern. Both are vastly colonized by Escherichia and Streptococcus but,
while humans display more Bifidobacterium, rodents bias towards more Lactobacillus [65,66]. In the
present study, the microbiota of the 8-day neonatal rat was dominated by Firmicutes (40%), Proteobacteria
(35%), and Actinobacteria (23%), being Lactobacillus, Escherichia, and Rothia, respectively, and the genera
represented more than 90% of the microbiota.
The main limitation of this study is the low number of samples analyzed for microbial composition
determination; that is why these interesting results should be carefully interpreted and taken into
account as a first approach for the dysbiosis caused by the RV and the effect of the oligosaccharides
tested here. In addition, the V3–V4 sequencing used here can also be improved in future studies by
using a metagenomic approach. Overall, based on these results, the infection with RV induced a
dysbiosis mainly by decreasing normally residing members, such as Streptococcus and Staphylococcus,
although it did not affect bacterial diversity. These findings are in line with a study of Chen et al. [12],
which showed a reduced Shannon Index only in severe but not mild, acute gastroenteritis in patients
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suffering from RV infection. In the same context, Li et al. [10] found decreased Shannon Index and
CHAO1 when infecting piglets with an homologous RV strain. It is well-known that an imbalanced
gut microbiota often arises from increases in Proteobacteria, which have been associated with a higher
inflammatory state and several diseases, such as colitis and metabolic syndrome [64,67]. This increase is
also present in the case of the RV group; in fact, some Proteobacteria that appeared have been attributed
to inflammatory properties, such as Klebsiella and Serratia, which are associated with necrotizing
enterocolitis and sepsis in premature infants [68]. When performing the PCA, it was striking that the
bacterial composition of those animals in the RV group clustered apart from the other individuals,
suggesting that RV infection evidently disturbed the normal microbiota composition.
The neonatal rat is a suitable model to assess the effects of the assayed oligosaccharides, such as
2’-FL and the mixture of scGOS/lcFOS. The first is globally one of the main oligosaccharides in human
milk, but it is not so abundant in rat milk, which is dominated mainly by 3’-sialyllactose (3’-SL) [69].
The well-studied prebiotic mixture of scGOS/lcFOS is produced from milk and vegetable sources
and induced similar microbial profiles as detected with infants receiving human milk [70]. The daily
nutritional intervention with these oligosaccharides was able to prevent the dysbiosis induced by the
RV infection (Figure 7).
It has been described that fucosylated human milk oligosaccharides, such as 2’-FL, may be
involved in the decrease of intestinal Proteobacteria, particularly in Enterobacteriaceae [31,68], which is
in line with the prevention of Proteobacteria-associated dysbiosis found here. Conversely, it has been
reported a positive correlation for 2’-FL and fecal bacteria from Firmicutes phylum [31,68]. In our study,
although the supplementation with 2’-FL did not show differences in the abundance of the Firmicutes
population, we observed that it promoted the growth of several genera (e.g., Staphylococcus and
Turicibacter) and the colonization of many new members, with a notable importance of nonpathogenic
Clostridium. Most of the Clostridium that appeared belonged to the clusters IV (e.g. C. leptum) and
XIVa (e.g. C. asparagiforme and C. lavalense), of which cultivated members are well-known for their
health-promoting activities arisen from the production of butyric acid, with anti-inflammatory and
immunomodulatory properties [71]. Moreover, Roseburia and Ruminococcus, genera included in the
Clostridium cluster XIVa, also appeared after the supplementation with 2’-FL. Several studies report a
depletion of butyrogenic bacteria belonging to clusters IV and XIVa in diseases coursing with dysbiosis,
including diarrhea [71–74]. In addition, it has been described that individuals with a greater abundance
of Ruminococcaceae might have lower susceptibility to RV infection [13].
Some of the effects displayed after the supplementation with 2’-FL were also seen by scGOS/lcFOS,
such as the colonization with Roseburia and Ruminococcus or the higher abundance of Staphylococcus
compared to the RV group. However, scGOS/lcFOS supplementation induced other specific effects, such
as promoting the colonization of 9 species-like groups within the Lactobacillus genus (e.g., L. gasseri and
L. rhamnosus). The combination of scGOS/lcFOS and 2’-FL displayed additive effects because it promoted
the colonization of butyrate-producing bacteria and prevented Streptococcus and Staphylococcus decrease
and the colonization of Proteobacteria.
The overall microbiota structure altering effects of these oligosaccharides were confirmed with
the PCA, which allowed seeing that the three supplements caused a different microbiota composition
compared to the RV group, suggesting that the beneficial effects for the prevention of the dysbiosis
occurred. In addition, the microbiota from the animals receiving oligosaccharides was more similar to
that of the REF group.
The data herein also suggested that many bacteria with probiotic characteristics are present in
higher abundances in individuals administered with oligosaccharides. In this sense, both dietary
interventions have showed a tendency to increase the abundance of bifidobacteria; however, this
effect has not been significantly evidenced maybe due to the dysbiosis caused by the RV and the low
levels of initial bifidobacteria present in suckling rats. Nevertheless, the growth promoting effect
of scGOS/lcFOS and 2’-FL in humans has been documented [31–33]. In infants, 2’-FL is shown to
increase the gut-predominant Bifidobacterium infantis and Bifidobacterium bifidum [75,76]. However,
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in suckling rats, the abundance of Bifidobacterium is much lower and the species which are present
(e.g. B. animalis and B. thermophilum) do not use 2’-FL as a source of energy [76]. Thus, the potential
growth of these beneficial bacteria by 2’-FL remains unclear, as it does not seem to be related to a direct
2’-FL catabolism [77]. In contrast, the higher abundance of probiotic bacteria might be linked to the
catabolism of scGOS/lcFOS, which has been shown to be a good energy source for many of the bacteria
identified [76,78,79]. However, the growth promoting effect of scGOS/lcFOS on Lactobacillus rhamnosus
and Bifidobcterium animalis did not appear when it was combined with 2’-FL, a fact that may suggest
that 2’-FL may be interfering somehow in the prebiotic effect of scGOS/lcFOS.
Finally, it would be interesting to study the role of these oligosaccharides in the context of an
anti-RV vaccination process in which their action preventing the dysbiosis induced by the virus could
have and additional value. In this line, they can be even more beneficial in those cases of severe RV
infection in which fecal microbiota transplantation could be an option either alone or in combination
with these components.
5. Conclusions
Despite the small sample size used in the present study, this first approach studying the effect
of certain oligosaccharides on microbiota composition supports a preventive effect of scGOS/lcFOS
and 2’-FL in the RV diarrhea in rats, which could be associated with changes in the microbiota–host
crosstalk and the microbiota composition. Moreover, the combination of scGOS/lcFOS and 2’-FL
maintains the specific effects of each compound by providing this mixture with higher benefits than
those induced by the compounds separately.
The infection with RV seemed to induce intestinal dysbiosis in terms of reducing normal residing
bacterial populations, such as Streptococcus and Staphylococcus, and of promoting the colonization with
many Proteobacteria with inflammatory potential. RV dysbiosis seemed successfully prevented by the
administration of all oligosaccharides, which in addition promoted a healthy microbiota comparable to
noninfected rats. Therefore, the supplementation with these oligosaccharides in early life, for example,
by adding them into infant formulas, seems to be a good strategy to prevent or treat RV infection and
its consequences.
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